Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 3, Issue 4, 2001, Pages 219-229

  Evans, Alison J ^a   Krentz, Andrew J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALCOHOL; ALPHA GLUCOSIDASE INHIBITOR; AMINO ACID DERIVATIVE; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CELL NUCLEUS RECEPTOR; CYTOKINE RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GUANIDINE DERIVATIVE; IMIDAZOLINE DERIVATIVE; INOSITOL DERIVATIVE; INSULIN DERIVATIVE; INSULIN RECEPTOR; LEPTIN; LEPTIN RECEPTOR; MEGLITINIDE; MEMBRANE RECEPTOR; MESSENGER RNA; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE INHIBITOR; SUCCINIC ACID DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VANADIUM DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPIDEMIC; ETHNIC DIFFERENCE; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PREVALENCE; RAT; REVIEW; TARGET ORGAN; TOBACCO; TREATMENT PLANNING;

EID: 0034851942     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00101.x     Document Type: Review

References (70)

1. Global estimates for prevalence of diabetes mellitus and IGT in adults
2. Pathogenesis of non-insulin-dependent diabetes mellitus
3. Insulin Resistance
4. Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance
5. Insulin resistance or insulin deficiency: Which is the primary cause of NIDDM?
6. Insulin resistance
7. Role of insulin resistance in human disease
8. Insulin resistance: A multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique
9. How to measure insulin action in vivo
10. Consensus development conference on insulin resistance
11. Role of insulin resistance in the pathogenesis of NIDDM
12. Prospective study of cigarette smoking, alcohol use and the risk of diabetes in men
13. Insulin resistance in smokers and other long-term users of nicotine
14. Drug treatment of hypertension in patients with diabetes mellitus
15. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
16. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients
17. Not all fat is alike
18. Central obesity: Measurement and metabolic effects
19. Dietary fat composition and human adiposity
20. The metabolically-obese, normal-weight individual revisited
21. Leptin in obesity
22. Leptin: Is it important in diabetes?
23. Obesity: A modern-day epidemic
24. Basal intermediary metabolism in impaired glucose tolerance and morbid obesity
25. Report
26. New diagnostic criteria for diabetes - Are they doing what they should?
27. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus
28. The fourth Musketeer: From Alexandre Dumas to Claude Bernard
29. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus
30. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications for the management of diabetes
31. Insulin action and non-esterified fatty acids
32. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
33. Fatty acids and insulin secretion
34. Cardiovascular actions of insulin in humans: Implications for insulin sensitivity and vascular tone
35. Hypothesis: Muscle insulin resistance is the ('not-so') thrifty genotype
36. Fetal origins of coronary heart disease
37. Physiologic programming of the fetus
38. Weighing in on diabetes risk
39. The fetal insulin hypothesis: An alternative explanation of the association of low birth-weight with diabetes and vascular disease
40. Insulin resistance and hypersecretion in obesity
41. Effect of loss of first phase insulin secretion on glucose production and disposal in man
42. Measurement of insulin secretion in type 2 diabetes: Problems and pitfalls
43. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes
44. Islet amyloid polypeptide: Does it play a pathophysiological role in the development of diabetes?
45. Prospective Diabetes Study 16: Overview of six years' therapy of type 2 diabetes: A progressive disease
46. Insulin resistance is central to the burden of diabetes
47. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: Errors of metabolism or of methods?
48. Is insulin resistance the principal cause of type 2 diabetes?
49. Comparative tolerability profiles of oral antidiabetic agents
50. UKPDS and beyond: Into the next millennium
51. Recent developments and emerging therapies for type 2 diabetes
52. Thiazolidinediones: A new class of oral antidiabetic drugs
53. PPAR-γ, the ultimate thrifty gene
54. FDA reviews troglitazone
55. Rosliglitazone and pioglitazone: New agents for type 2 diabetes
56. Repaglinide: A new short-acting hypoglycaemic agent
57. The polycystic ovary syndrome: Treatment with insulin-sensitizing agents
58. Benefits and risks of transfer from oral antidiabetic agents to insulin in type 2 diabetes
59. Insulin analogues and their potential in the management of diabetes mellitus
60. A drug on the market?
61. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
62. Pharmacotherapy for obesity: Do the benefits outweigh the risks?
63. Prevalence and determinants of valvopathy in patients treated dexfenfluramine
64. Sibutramine: A review of its contribution to the management of obesity
65. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
66. Relation between leptin and the regulation of glucose metabolism
67. Obesity treatment
68. Preventing non-insulin-dependent diabetes
69. The accelerating need for pharmacovigilance
70. Diabetes: A time for excitement and concern